VolitionRx Limited

NYSEAM:VNRX Stock Report

Market Cap: US$6.4m

VolitionRx Future Growth

Future criteria checks 2/6

VolitionRx is forecast to grow earnings and revenue by 53.2% and 53.5% per annum respectively while EPS is expected to grow by 62.3% per annum.

Key information

53.2%

Earnings growth rate

62.33%

EPS growth rate

Medical Equipment earnings growth17.3%
Revenue growth rate53.5%
Future return on equityn/a
Analyst coverage

Good

Last updated07 Jul 2026

Recent future growth updates

Recent updates

Narrative Update • Jul 24

VNRX: New Diagnostics Progress And Reduced Share Authorization Will Drive Repricing

Analysts lifted their fair value estimate for VolitionRx from $3.00 to $24.00, citing updated assumptions for revenue growth, profitability, discount rate, and a higher future P/E multiple that align with recent Street research pointing to potential progress across the Nu.Q diagnostic portfolio. What’s in the News for VolitionRx On July 17, 2026, VolitionRx reduced its authorized common stock under its Restated Certificate of Incorporation from 325,000,000 to 150,000,000 shares, following board approval on May 11, 2026 and shareholder approval at the annual meeting on July 17, 2026.
Narrative Update • Jul 10

VNRX: Lung Cancer Study Progress Will Drive Repricing Potential

Analysts have lifted their fair value estimate for VolitionRx to about $17 from roughly $2, citing updated assumptions on discount rate, revenue growth, profit margin, and future P/E. These changes reflect a mix of renewed optimism following Maxim's resumed Buy coverage at a $4 price target and more cautious views after the recent downgrade at D.
Narrative Update • Jun 26

VNRX: Turnaround Case Will Rely On Diagnostic Portfolio Commercial Traction

Analysts have lifted their price target on VolitionRx from $1.00 to $4.00, citing expectations for progress across the Nu.Q Vet, Nu.Q NETs, and Nu.Q Cancer franchises, along with updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent Street research on VolitionRx highlights a mix of optimism and caution, with the latest $4 price target sitting alongside earlier, more cautious views and adjustments.

Earnings and Revenue Growth Forecasts

NYSEAM:VNRX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202822-1014-63
12/31/20276-20-2-213
12/31/20262-22-16-216
3/31/20262-25-21-21N/A
12/31/20252-23-20-20N/A
9/30/20251-23-20-20N/A
6/30/20251-23-22-21N/A
3/31/20251-24-22-22N/A
12/31/20241-27-26-26N/A
9/30/20241-30-15-14N/A
6/30/20241-32-18-17N/A
3/31/20241-35-19-18N/A
12/31/20231-35-19-18N/A
9/30/20231-34-32-30N/A
6/30/20231-33-30-29N/A
3/31/20230-31-29-28N/A
12/31/20220-30-17-15N/A
9/30/20220-31-15-14N/A
6/30/20220-30-13-12N/A
3/31/20220-28-12-11N/A
12/31/20210-27-22-21N/A
9/30/20210-24-21-19N/A
6/30/20210-21-21-19N/A
3/31/20210-21-20-18N/A
12/31/20200-20-18-16N/A
9/30/20200-19-17-16N/A
6/30/20200-19-16-16N/A
3/31/20200-18-15-14N/A
12/31/20190-16N/A-13N/A
9/30/20190-17N/A-14N/A
6/30/2019N/A-17N/A-15N/A
3/31/2019N/A-18N/A-15N/A
12/31/2018N/A-18N/A-15N/A
9/30/2018N/A-18N/A-15N/A
6/30/2018N/A-17N/A-13N/A
3/31/2018N/A-16N/A-13N/A
12/31/2017N/A-15N/A-12N/A
9/30/2017N/A-14N/A-10N/A
6/30/2017N/A-13N/A-10N/A
3/31/2017N/A-13N/A-9N/A
12/31/2016N/A-12N/A-9N/A
9/30/2016N/A-12N/A-9N/A
6/30/2016N/A-11N/A-9N/A
3/31/2016N/A-10N/A-9N/A
12/31/2015N/A-10N/A-9N/A
9/30/20150-8N/A-7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VNRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VNRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VNRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VNRX's revenue (53.5% per year) is forecast to grow faster than the US market (12.7% per year).

High Growth Revenue: VNRX's revenue (53.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if VNRX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/07 07:05
End of Day Share Price 2026/08/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

VolitionRx Limited is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Bruce JacksonBenchmark Company
Jan WaldBenchmark Company